12.2 CKD-MBD Pharmacotherapy: Binders, Vitamin D & Calcimimetics

CKD-MBD Pharmacotherapy: Binders, Vitamin D & Calcimimetics

Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) is a complex systemic syndrome driven by progressive nephron loss that impairs mineral homeostasis. As glomerular filtration rate drops, phosphate retention, calcitriol deficiency, and parathyroid gland hyperplasia trigger secondary hyperparathyroidism (sHPT), renal osteodystrophy, and extra-skeletal vascular and valvular calcification. The pharmacologic management of CKD-MBD rests upon three interconnected therapeutic classes: gastrointestinal phosphate binders, vitamin D receptor activators (VDRAs), and calcimimetics.

---

Phosphate Binders: Mechanism & Administration Rules

Restrict excessive calcium-binder exposure based on serial values, calcification risk and the prescribed plan; old fixed calcium intake caps are not a universal current mandate.

The Fundamental Mealtime Administration Rule

Phosphate binders act within the gastrointestinal tract to reduce absorption of dietary phosphate. Administer the selected product with meals as labeled so it encounters the phosphate load. Clarify missed meals and doses through the prescribed plan; there is no universal 10–15-minute window that applies to every binder. Calcium- and iron-containing products can contribute systemic mineral exposure, whereas sevelamer is not absorbed.

---

Classes of Phosphate Binders

1. Calcium-Based Phosphate Binders

• Calcium Acetate (PhosLo, 667 mg): Contains $169\text{ mg}$ ($8.45\text{ mEq}$) of elemental calcium per capsule or tablet. Calcium acetate binds twice as much dietary phosphorus per gram of elemental calcium compared to calcium carbonate, allowing effective binding at lower total calcium exposure.
• Calcium Carbonate (Tums, Caltrate): Contains 40% elemental calcium ($500\text{ mg}$ elemental calcium per $1,250\text{ mg}$ tablet). It requires an acidic gastric environment to dissociate and is significantly less effective in patients taking proton pump inhibitors (PPIs) or H2-receptor antagonists. Restrict excessive calcium-based binder exposure according to serial calcium, phosphorus, PTH and vascular-calcification risk; older fixed calcium intake caps are not a universal current KDIGO mandate. Low PTH raises concern for low turnover; review therapy using assay limits and trends rather than an automatic diagnosis or universal hold threshold.

2. Non-Calcium, Non-Aluminum Binders

• Sevelamer Carbonate (Renvela) & Sevelamer Hydrochloride (Renagel): An unabsorbed, cross-linked poly(allylamine) polymer. In the gut lumen, the polymer expands and binds phosphate anions via ion exchange and hydrogen bonding. The carbonate salt is preferred over the hydrochloride salt because sevelamer hydrochloride can induce or worsen metabolic acidosis. Beyond phosphate control, sevelamer binds bile acids, producing a 15% to 30% reduction in LDL cholesterol. Adverse effects are predominantly gastrointestinal: dyspepsia, nausea, constipation, flatulence, and rare instances of fecal impaction or intestinal perforation.
• Lanthanum Carbonate (Fosrenol): A chewable tablet containing the rare earth trivalent cation lanthanum ($La^{3+}$), which exhibits high binding affinity for phosphate across a wide pH range (1 to 7). Mandatory nursing instruction: Tablets must be chewed completely to a fine powder before swallowing. Swallowing whole tablets has caused esophageal impaction, bowel obstruction, and intestinal perforation. Furthermore, lanthanum is radiopaque and appears as dense, radio-opaque particulate densities on abdominal X-rays, which can be mistaken for retained surgical foreign bodies or contrast material.

3. Iron-Based Phosphate Binders

• Ferric Citrate (Auryxia): Binds dietary phosphate in the gut. A portion of the ferric iron is reduced to ferrous iron and absorbed systemically, increasing transferrin saturation and ferritin. This dual mechanism can decrease IV iron and ESA requirements, but patients require ferritin monitoring to avoid iron overload.
• Sucroferric Oxyhydroxide (Velphoro): A chewable polynuclear iron(III)-oxyhydroxide formulation with high phosphate binding capacity and minimal systemic iron absorption. It causes benign, dark-colored stools, requiring patient reassurance to prevent confusion with gastrointestinal hemorrhage.

4. Aluminum Hydroxide (Historical Salvage)

Avoid long-term aluminum binders because of neurotoxicity, osteomalacia and anemia. Any limited specialist-directed use follows an individualized plan, not a mandatory rescue course.

Phosphate Binders Comparison Table

---

Vitamin D Sterols & Selective VDRA Analogs

In healthy kidneys, mitochondrial 1-alpha-hydroxylase in proximal tubules converts 25-hydroxyvitamin D into biologically active 1,25-dihydroxyvitamin D [$1,25(OH)_2D_3$, calcitriol]. Advanced kidney failure markedly impairs this conversion, precipitating hypocalcemia and removing parathyroid chief cell feedback inhibition.

Active vitamin D can increase calcium and phosphorus absorption; monitor both values and PTH trends rather than treating a calcium-phosphorus product cutoff as the sole target. Paricalcitol and other vitamin-D-receptor activators suppress PTH but still require calcium/phosphorus surveillance; they do not eliminate hypercalcemia risk.

---

Calcimimetics: Allosteric CaSR Modulation

Calcimimetics represent a breakthrough class that targets the Calcium-Sensing Receptor (CaSR), a 7-transmembrane G-protein-coupled receptor on parathyroid chief cells.

Mechanism of Action

Calcimimetics are allosteric modulators of the CaSR. By binding to the transmembrane domain, they induce a conformational change that increases the receptor's affinity for extracellular ionized calcium ($Ca^{2+}$). Chief cells perceive ambient calcium levels as significantly higher than they actually are. This downregulates PTH synthesis and exocytosis within hours. Unlike vitamin D sterols, calcimimetics lower parathyroid hormone while simultaneously decreasing serum calcium and phosphorus.

Cinacalcet vs. Etelcalcetide

• Cinacalcet (Sensipar): An oral calcimimetic tablet. It must be taken with food or shortly after meals because food increases its bioavailability by 50% to 80% and mitigates upper GI irritation. Common side effects include nausea and vomiting (up to 30% of patients).
  • Starting versus ongoing therapy: Cinacalcet initiation is contraindicated below the laboratory lower normal calcium limit. During maintenance, follow the label and ordered calcium-management plan; not every value below 8.4 mg/dL requires an identical hold. Etelcalcetide avoids oral dosing but can still cause nausea, vomiting and other adverse effects. Give it only after blood is no longer circulating through the dialyzer, with the labeled rinseback/flush procedure.

Distinguish starting therapy from maintaining it. Cinacalcet initiation is contraindicated below the laboratory lower normal calcium limit. For maintenance calcium between 7.5 and 8.4 mg/dL, labeling allows calcium/vitamin-D measures and clinical dose review; below 7.5 mg/dL or persistent symptoms, withhold according to the label and ordered plan. Do not apply a blanket mandatory hold at every value below 8.4. Etelcalcetide has serious hypocalcemia warnings but no boxed warning. Give it only after blood is no longer passing through the dialyzer, using the labeled venous-line/rinseback or post-rinseback technique and flush volume. Corrected calcium estimates are imperfect in dialysis; obtain ionized calcium when a reliable physiologic assessment is needed. Long-term aluminum binder use is avoided because of toxicity; any short specialist-directed course is not a mandatory rescue regimen.

Sources checked 2026-10-10: KDIGO CKD-MBD and etelcalcetide label